相关实验视频

Updated: Jan 8, 2026

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry
08:04

Analyzing Platelet Subpopulations by Multi-color Flow Cytometry

Published on: June 10, 2025

1.3K

在阳性夜间血红蛋白尿症中,C3突变和基甲基普兰反应差

Santiago Rodríguez de Córdoba1, Andrea Reparaz Suevos1, Silvia González Sanz1

  • 1Centro de Investigaciones Biológicas Margarita Salas (CIB-MS), Madrid, Spain.

Frontiers in immunology
|December 12, 2025
PubMed
概括

在C3MG环中的突变导致对补充抑制剂的耐药性,导致帕洛克斯性夜间血红蛋白尿症 (PNH) 的治疗挑战. 这一发现凸显了基因测试的必要性,以指导PNH治疗.

关键词:
AP50 AP50 AP50 AP50 AP50 AP50 AP50 AP50 AP50 AP50 AP50 AP50补充补充补充补充补充补充补充.在此之前,Eculizumab也曾被使用过.遗传学 遗传学 遗传学 是一个佩格塞塔科普拉纳的平面.

更多相关视频

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity11:13

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

9.1K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

相关概念视频

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
415